Moximed Welcomes Michael Mydra as Senior Vice President of Reimbursement
Moximed, a leader in innovative medical devices, has announced the addition of Michael Mydra to its team as the Senior Vice President of Reimbursement and Market Access. This appointment aims to reinforce the company’s commitment to enhancing care for individuals suffering from knee osteoarthritis (OA).
Michael Mydra's Expertise and Experience
Michael Mydra is recognized for his remarkable track record in achieving critical coding, coverage, and payment strategies for groundbreaking medical technologies. Chris Gleason, the President and CEO of Moximed, expressed enthusiasm about Michael joining the Moximed team, noting that his background in establishing five Category I CPT codes will be invaluable as the company seeks to broaden access to the MISHA Knee System.
Previous Roles Contributing to His Success
Before joining Moximed, Michael Mydra held a pivotal position as the Senior Vice President of Reimbursement and Market Access at PainTEQ, Inc. His extensive experience spans a variety of roles in reimbursement and market access across several well-regarded medical technology firms, including Sanarus Medical, Vertos Medical, SI-BONE, Boston Scientific, and Profound Medical.
A Vision for Expanding Access to Treatment
In reflecting on his new role, Michael expressed, "It is an honor to join the talented team at Moximed. The clinical evidence supporting the MISHA Knee System is robust and will continue to grow. I am eager to help expand access to this disruptive technology as we look to transform the lives of millions of people affected by knee osteoarthritis." His enthusiasm underscores the potential impact of Moximed’s advancements in OA treatment.
What is the MISHA Knee System?
The MISHA Knee System is designed specifically for patients suffering from medial knee OA who have not found relief through other treatments. Many of these individuals continue to endure significant pain, making daily activities cumbersome. This demographic often includes those who are not suitable for joint replacement surgery due to age or the absence of advanced OA. Total knee replacements are usually a last resort for patients with serious illness. Thus, the need for effective alternatives is paramount.
Understanding Osteoarthritis and Treatment Needs
Knee OA arises when the natural shock-absorbing structures of the joint—such as cartilage and meniscus—start failing. This deterioration results in chronic pain and limits individuals' daily activities. Many people dealing with mild to moderate OA are otherwise active and healthy, often unwilling to consider total knee replacement, which indicates advanced disease. Therefore, preserving knee function and facilitating a better quality of life remain high priorities for these patients.
How the MISHA Knee System Works
Research has shown that offloading painful osteoarthritic joints can alleviate discomfort and enhance function. The MISHA Knee System distinguishes itself as the first implantable shock absorber, designed to reduce stress on the knee joint with every step taken. This innovative approach allows users to experience pain relief and potentially postpone the need for more invasive procedures like joint replacement. Placed on the medial side of the knee, the system synchronizes with natural joint movements, diminishing peak forces on the knee by approximately 30% with each step.
Commitment to Quality and Safety
Moximed’s MISHA Knee System has received FDA clearance, affirming its safety and efficacy for users. This significant milestone highlights Moximed's dedication to advancing care standards for individuals suffering from knee OA through innovative solutions.
About Moximed
Headquartered in Fremont, California, Moximed’s innovative technology is the culmination of over ten years of clinical research and development. The MISHA Knee System represents the first implantable shock absorber targeting the treatment of medial compartment knee OA. Moximed is committed to improving the standard of care and enhancing the quality of life for millions of individuals battling knee pain associated with osteoarthritis.
Frequently Asked Questions
What role has Michael Mydra taken on at Moximed?
Michael Mydra has joined Moximed as Senior Vice President of Reimbursement and Market Access, focusing on expanding access to innovative treatments.
What is the MISHA Knee System designed for?
The MISHA Knee System is specifically developed for patients with medial knee OA who have not found relief through other treatments and who aren't ready for joint replacement.
How does the MISHA Knee System alleviate knee pain?
The MISHA Knee System acts as an implantable shock absorber, reducing weight on the knee joint with each step, thereby easing pain and improving function.
Is the MISHA Knee System FDA approved?
Yes, the MISHA Knee System has received FDA clearance, confirming its safety for patients with knee osteoarthritis.
Where is Moximed located?
Moximed is headquartered in Fremont, California, and is committed to advancing treatment options for knee osteoarthritis sufferers.
